ASCO GU 2019 - Results from #20

Viewing 21-40 of 154 articles

ASCO GU 2019: TIVO-3: A Phase III, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma

ASCO GU 2019: JAVELIN Renal 101: Outcomes for Avelumab + Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma (RCC)

ASCO GU 2019: Multidisciplinary Tumor Board: Case-Based Discussion on Kidney Cancer

ASCO GU 2019: Efficacy and safety of Nivolumab on Patients with Non-Clear Cell Renal Cell Carcinoma: Results from the Phase IIIb/IV CheckMate 374 Study

ASCO GU 2019: Results from KEYNOTE-427 Cohort Bb - First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell RCC

ASCO GU 2019: Final Analysis from the NIVOREN GETUG AFU 26 Study

ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma

ASCO GU 2019: Health-Related Quality of Life Reporting in Phase III Randomized Controlled Trials of Metastatic Prostate Adenocarcinoma and Urothelial Carcinoma

ASCO GU 2019: Study of Durvalumab Given with Chemotherapy, Durvalumab in Combination with Tremelimumab Given with Chemotherapy, or Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

ASCO GU 2019: Gemcitabine-Carboplatin versus Gemcitabine-Oxaliplatin In Cisplatin Un-Fit Advanced Urothelial Carcinoma: Randomized Phase II Study-COACH Study

ASCO GU 2019: RENAVIV: Pazopanib with or without Abexinostat in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

ASCO GU 2019: PROSPER: Comparing Perioperative Nivolumab versus Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy

ASCO GU 2019: Gemcitabine Plus Axitinib in Patients with Sarcomatoid Type Renal Carcinoma

ASCO GU 2019: Novel Predictive Models of Early Death Less than One Year in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors

ASCO GU 2019: Results of a Phase II Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with mRCC

ASCO GU 2019: A Phase II study of Cabozantinib as First-line Treatment in Metastatic Collecting Duct Carcinoma: The BONSAI Trial

ASCO GU 2019: CheckMate 9UT - Nivolumab or Nivo Plus BMS-986205 with or without Intravesical Bacillus Calmette-Guerin in BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

ASCO GU 2019: POTOMAC Study - Durvalumab and BCG versus BCG Alone in High-risk, BCG-Naïve Non Muscle-Invasive Bladder Cancer

ASCO GU 2019: Renal Function Preservation in Kidney Cancer: Current Techniques and Biomarkers

ASCO GU 2019: Phase II Study of Ribociclib in Men with Unresectable, Incurable Teratoma with Recent Progression

1
2
3
4
5
6
7
8